AZN's Daiichi Sankyo-partnered datopotamab deruxtecan fails to show overall survival benefits in a breast cancer study. Stock ...

Analysis of the TROPION-Breast01 study showed that treatment with Dato-DXd did not significantly improve overall survival ...

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...

If approved, AZN's Fasenra will be the second biologic approved in the European Union to treat eosinophilic granulomatosis ...

The overall survival, or OS rates, in the TROPION-Breast01 Phase III trial of datopotamab deruxtecan (Dato-DXd), did not ...

A cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer ...

A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ...

This briefing covers notable health news: the US is donating 1 million mpox vaccine doses to Africa, AstraZeneca’s breast ...

AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve ...

AstraZeneca updated the market on two ongoing drug trials on Monday, with a key trial in breast cancer failing to improve ...

Datopotamab deruxtecan is a TROP2-directed DXd ADC engineered by Daiichi Sankyo and co-developed by AstraZeneca and Daiichi Sankyo. The data pertaining to this compound will be presented at an ...